Lunit’s clinical intelligence platform spans AI-powered cancer diagnostics, detection, treatment planning, and biomarker/CDx development—bringing together a range of solutions designed to work seamlessly across the care continuum.
More than standalone tools, these clinically validated systems serve as engines of insight—powered by diverse, large-scale data and built for interoperability and synergy.
Together, they form the foundation for a future-ready, multimodal approach to innovation in cancer care at scale.

We train our AI solutions on millions of expertly annotated images—including CXR, MMG, DBT, H&E, and IHC—sourced through global clinical partnerships. This high-quality, diverse dataset drives more reliable, generalizable performance across cancer applications.

With FDA-cleared and CE-marked (under MDR) products used at 10,000+ sites in 65+ countries, our AI cancer solutions are clinically validated and globally trusted.

We’re optimizing adaptable AI to meet the needs of modern cancer care, improving performance through continuous R&D and strategic acquisitions. As a long-term innovation partner, we’re advancing toward a scalable future built on next-generation foundation models.

Our multimodal AI leverages diverse data types across domains—imaging, clinical, tissue, and molecular—to power more accurate detection, personalized risk stratification, advanced spatial analysis, and innovative biomarker development.
Access product guides, clinical papers, and practical tools. Everything your team needs to evaluate and implement Lunit’s technology in real-world care settings.
